The European Medicines Agency issued positive opinions for 104 new medicines in 2025 of which 38 were drugs with new active substances, according to the agency’s annual human medicines report issued on 15 January. At 38, the number is fewer than the 46 novel drugs recommended during the previous year, but no less impactful.
GSK Plc has reach an agreement to acquire US-based RAPT Therapeutics Inc for $2.2 billion, strengthening its position in the field of medicines for inflammatory and immunologic diseases. The US company’s lead product, ozureprubart, is a monoclonal antibody that is being developed as a prophylactic against food allergens. It targets immunoglobulin E (IgE) which is the mode of action of at least one other approved biologic. Other treatments include allergen-specific immunotherapies. The standard of care is avoidance of allergens.
Follicular lymphoma is a type of slow-growing blood cancer affecting B lymphocytes, a type of white blood cell that plays a critical role in immunity. There are many types of lymphomas but follicular is distinctive because of its tendency to grow slowly, starting in the follicules of lymph nodes and then expanding outwards. There are multiple approaches for treating the disease including an early observational phase known as ‘watch and wait’ where physicians monitor patients to identify symptoms that could justify a pharmaceutical treatment.
Case Study
How argenx reached
Nasdaq as a small European biotech
Research Strategy
Epigenetic modulation in
pulmonary disease
By Björn Dahlöf
Interview
Exploring novel payloads
for antibody-drug conjugates
Interview with Adcytherix
Cell and Gene Therapy
Why synthetic gene
promoters matter
By Thilo Pohle
